Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung

A. Ardizzoni, L. Canobbio, P. Pronzato, A. Rubagotti, M. De Palma, F. Baracco, J. Serrano, S. Serrano, B. Faravelli, M. Nosenzo

Research output: Contribution to journalArticle

Abstract

Fifty patients with advanced squamous cell carcinoma and adenocarcinoma of the lung having good prognostic features (performance status ≤ 2; weight loss ≤ 10%; and age ≤ 70 years; absence of brain metastases; and no prior treatment) were treated on an outpatient basis with etoposide (120 mg/m2 on Days 1, 3, and 5) and cisplatin (60 mg/m2 on Days 1 and 2) every 21-28 days. One complete response and 14 partial responses were observed, with a median duration of response of 170 days and an overall median survival of 230 days. Toxicity was generally mild. Despite the high-dose cisplatin employed and the choice of patients with favorable prognostic factors in this study, results of this therapy remain disappointing.

Original languageEnglish
Pages (from-to)891-892
Number of pages2
JournalCancer Treatment Reports
Volume70
Issue number7
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung'. Together they form a unique fingerprint.

  • Cite this

    Ardizzoni, A., Canobbio, L., Pronzato, P., Rubagotti, A., De Palma, M., Baracco, F., Serrano, J., Serrano, S., Faravelli, B., & Nosenzo, M. (1986). Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treatment Reports, 70(7), 891-892.